Synbio International Inc. has received approval for Deposit/Withdrawal at Custodian and Direct Registration System processing through its transfer agent, Pacific Stock Transfer Company. This development represents a critical modernization of the company's trading infrastructure that improves accessibility for both current shareholders and potential investors.
The DWAC eligibility enables electronic transfer of shares between broker-dealers and the company's transfer agent, eliminating the need for physical share certificates. This technological advancement reduces settlement times and lowers transaction friction, creating more efficient trading in the open market. Parallel DRS implementation allows shareholders to hold shares directly on the company's books in electronic form without requiring physical certificates or intermediary custody, providing investors with greater control, enhanced ownership security, and simplified transferability.
Claudio Solitario, CEO of Synbio International, emphasized that achieving DWAC and DRS eligibility represents a foundational step in strengthening the company's capital markets platform. As Synbio continues to advance strategic initiatives including planned financing activities and partnership developments, having stock that is easily accessible and efficiently tradable becomes critical for the investment community. This positions the company to move quickly as it executes on multiple near-term initiatives currently in progress.
This infrastructure enhancement comes as Synbio continues transitioning toward a more investor-ready, execution-focused public company platform. The company expects multiple near-term capital markets and operational catalysts. Synbio International operates as a medical research and technology company focused on clinically validated AI-driven medical diagnostics, working through strategic partnerships and research collaborations to bridge the gap between wellness and medicine. The company develops science-based solutions that improve quality of life and empower healthcare providers, with additional information available at https://www.synbiointl.com.
The importance of this development extends beyond technical infrastructure improvements. For individual investors, the elimination of physical certificates and reduced settlement times means faster access to capital and simplified portfolio management. For the broader market, this modernization represents how emerging companies are adapting to contemporary trading expectations, potentially setting standards for other OTC-listed companies seeking to improve investor accessibility. The enhanced trading efficiency could facilitate greater liquidity and potentially broader institutional interest as Synbio executes its strategic initiatives in the medical diagnostics sector.
